
AACR 2023 – more hope for Moderna’s neoantigen immunotherapy
After Moderna/Merck & Co’s December splash, full data from Keynote-942 stand up to scrutiny.

Key second-quarter clinical readouts for pharma
Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.

Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression
39% of the patients assessed carried this biomarker, the conference presentation reveals.